About This Dossier

What the dossier covers

Aus Peptide is a dossier on the published research behind three peptides discussed under the loose banner of the growth hormone (GH) axis: CJC-1295/Ipamorelin, MOTS-c, and sermorelin, with sermorelin as the lead compound because it carries by far the deepest clinical-trial record of the three. The organizing frame is GHRH and GHRP research peptides, side by side — a deliberately narrow lens that groups two GHRH-receptor-facing compounds (sermorelin, and the CJC-1295 half of the combination) with one ghrelin-receptor-facing compound (ipamorelin), and, honestly, one outlier that does not fit the frame mechanistically at all (MOTS-c).

That outlier is here on purpose, not by accident. Research-use communities interested in GH-axis peptides for sleep, recovery, and body composition very often look into MOTS-c in the same breath, even though its actual biology — mitochondrial signaling and AMPK/CK2 activation — has nothing to do with the pituitary. The dossier handles that honestly: each compound page states plainly what a peptide's mechanism actually is, rather than forcing every entry into a tidy shared narrative for the sake of a clean category page.

How the dossier is kept

Three habits govern the dossier.

Every research claim ties to a citation. Peer-reviewed journal articles, clinical-trial reports, and authoritative reviews are collected, numbered, and linked with DOIs and PubMed identifiers on the references page; a claim without a number behind it is either general background or explicitly framed as an anecdotal community report.

Evidence is described at the strength it was actually generated with. A single-dose pharmacokinetic study in healthy adults is not written up like a randomized, placebo-controlled trial in a clinical population, and a mouse study is never quietly passed off as a human result. Where a combination like CJC-1295/Ipamorelin has never itself been tested, the dossier says so outright rather than blending single-agent data into an implied combination result.

Community-reported effects are labeled as exactly that. Where research-use communities describe benefits or side effects never measured in a controlled study, the dossier presents them clearly as anecdotal — useful context, not evidence, and never a basis for a recommended dose.

The boundaries

Aus Peptide is not a pharmacy, a clinic, a telehealth platform, or a peptide seller. It sells, sources, and brokers nothing discussed here, and it holds no referral or affiliate tie to any supplier, clinic, or manufacturer. It does not diagnose, prescribe, or name a dose, schedule, or route for any individual, and nothing here should be read as a substitute for care from a licensed clinician.

Sermorelin is available through compounding pharmacies under a licensed prescriber's direction; CJC-1295, ipamorelin, and MOTS-c are, as of this writing, sold only as research chemicals with no approved human indication. A reader seeking clinical guidance on growth-hormone-axis concerns should consult a licensed healthcare provider. Editorial correspondence — a citation correction, a newly published trial, a regulatory update — can go to the contact page; the dossier reads that mail carefully and cannot answer requests for medical advice.